Alunbrig (brigatinib) — United Healthcare
metastatic brain cancer from NSCLC
Initial criteria
- Diagnosis of metastatic brain cancer from NSCLC
- Tumor is anaplastic lymphoma kinase (ALK)-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Alunbrig therapy
Approval duration
12 months